Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.42 |
| ▸ | DPP4 | P27487 | 3/20 | 0.42 |
| ▸ | NPY4R | P50391 | 9/20 | 0.41 |
| ▸ | NPY1R | P25929 | 5/20 | 0.41 |
| ▸ | NPY2R | P49146 | 4/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.41 |
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006420 | 0.86 | SIRT6 (0.47) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL14627405 | 0.83 | GNAI3 (0.51) | DPP7GNAI3GNAO1GNAI1DPP8 | |
| Hydrochloric Acid SCHEMBL446543 | 0.82 | GNAI3 (0.50) | DPP7GNAI3GNAO1GNAI1DPP8 | |
| SCHEMBL2182733 | 0.81 | DPP7 (0.51) | DPP7GNAI3GNAO1GNAI1DPP8 | |
| SCHEMBL1521786 | 0.81 | DPP7 (0.49) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| SCHEMBL1521224 | 0.81 | DPP7 (0.49) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| SCHEMBL1004635 | 0.81 | DPP7 (0.47) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| SCHEMBL1521539 | 0.80 | NPY4R (0.46) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| SCHEMBL1521162 | 0.79 | NPY4R (0.47) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| SCHEMBL446551 | 0.79 | GNAI3 (0.49) | DPP7GNAI3GNAO1GNAI1DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778871-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8765909-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20110312898-A1 | PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2379053-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110059888-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-10 | — | — | US | disclosed |
| US-7786083-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| WO-2010076896-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-08 | — | — | WO | disclosed |
| US-20090298765-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-03 | — | — | US | disclosed |
| US-7625869-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-01 | — | — | US | disclosed |
| EP-2113513-A2 | Metastin derivatives and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-20090215700-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-2081955-A1 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| WO-2008050897-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | disclosed |
| EP-1758932-A2 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006001499-A2 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215700-A1 | Metastin derivatives and use thereof | SHBG, GNRHR, INHA | DPP7 135/4885GNAI3 149/4885GNAO1 373/4885 |
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | GNRHR, SHBG, MEN1 | DPP7 68/4885GNAI3 377/4885GNAO1 513/4885 |
| US-20110312898-A1 | PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER | KLK3, SHBG, SERPINA3 | DPP7 155/4885GNAI3 1723/4885GNAO1 1449/4885 |
| US-20110059888-A1 | METASTIN DERIVATIVES AND USE THEREOF | SHBG, GNRHR, INHA | DPP7 135/4885GNAI3 149/4885GNAO1 373/4885 |
| US-20090298765-A1 | Metastin derivatives and use thereof | GNRHR, SHBG, MEN1 | DPP7 68/4885GNAI3 377/4885GNAO1 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.